Predicting development of sustained unresponsiveness to milk oral immunotherapy using epitope-specific antibody binding profiles Mayte Suárez-Fariñas,

Slides:

Advertisements

Similar presentations

A bioinformatics approach to identify patients with symptomatic peanut allergy using peptide microarray immunoassay Jing Lin, PhD, Francesca M. Bruni,

Advertisements

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

The natural history of soy allergy

The use of serum-specific IgE measurements for the diagnosis of peanut, tree nut, and seed allergy Jennifer M. Maloney, MD, Magnus Rudengren, BSc, Staffan.

Corinne A. Keet, MD, MS, Pamela A

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy Satya D. Narisety,

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial Stephen.

Effects of time, albuterol, and budesonide on the shape of the flow-volume loop in children with asthma Anand C. Patel, MD, Mark L. Van Natta, MHS, James.

Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy Michael Kulis, PhD, Katie.

An IL-17–dominant immune profile is shared across the major orphan forms of ichthyosis Amy S. Paller, MD, MS, Yael Renert-Yuval, MD, Maria Suprun, MPH,

Advances in food allergy in 2015

Ann-Marie M. Schoos, MD, PhD, Jacob D

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults Peter S. Creticos, MD, Jennifer Maloney,

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD

Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis Jennifer D. Hamilton, PhD, Mayte Suárez-Fariñas,

Early recovery from cow's milk allergy is associated with decreasing IgE and increasing IgG4 binding to cow's milk epitopes Emma M. Savilahti, MD, Ville.

Correlation of IgE/IgG4 milk epitopes and affinity of milk-specific IgE antibodies with different phenotypes of clinical milk allergy Julie Wang, MD,

Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy Pamela A. Frischmeyer-Guerrerio, MD,

Decreased response to inhaled steroids in overweight and obese asthmatic children Erick Forno, MD, MPH, Rachel Lescher, MD, Robert Strunk, MD, Scott Weiss,

A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy Robert A.

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

The effects of house dust mite sublingual immunotherapy tablet on immunologic biomarkers and nasal allergen challenge symptoms Natasha C. Gunawardana,

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial Stephen.

Intravenous anti–IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis Marc E. Rothenberg, MD, PhD, Ting Wen, PhD, Allison Greenberg, BA, Oral.

Correction Journal of Allergy and Clinical Immunology

Allergy testing in predicting outcome of open food challenge to peanut

A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy Justin M. Skripak, MD, Scott D. Nash, MD, Hannah.

Immune factors in breast milk related to infant milk allergy are independent of maternal atopy Kirsi M. Järvinen, MD, PhD, Mayte Suárez-Fariñas, PhD,

Molecular phenotyping of severe asthma using pattern recognition of bronchoalveolar lavage–derived cytokines Allan R. Brasier, MD, Sundar Victor, MS,

Early-life gut microbiome composition and milk allergy resolution

Treatment of chronic autoimmune urticaria with omalizumab

Elina Jerschow, MD, MSc, Robert Y. Lin, MD, MSc, Moira M

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

Peanut epitopes for IgE and IgG4 in peanut-sensitized children in relation to severity of peanut allergy Annebeth E. Flinterman, MD, Edward F. Knol,

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy Satya D. Narisety,

Jewlya Lynn, PhD, Sophie Oppenheimer, MS, MPH, Lorena Zimmer, MA

A. Wesley Burks, MD, Robert A. Wood, MD, Stacie M. Jones, MD, Scott H

Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors Donald W. MacGlashan, MD, PhD,

Donald W. MacGlashan, MD, PhD, Sarbjit S. Saini, MD

Anna Nowak-Wegrzyn, MD, Katherine A. Bloom, MD, Scott. H

Peanut oral immunotherapy modifies IgE and IgG4 responses to major peanut allergens Brian P. Vickery, MD, Jing Lin, PhD, Michael Kulis, PhD, Zhiyan Fu,

Cluster analysis and prediction of treatment outcomes for chronic rhinosinusitis Zachary M. Soler, MD, MSc, J. Madison Hyer, MS, Luke Rudmik, MD, MSc,

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial Hendrik.

Allergen-specific immunotherapy with recombinant grass pollen allergens Marek Jutel, MD, Lothar Jaeger, MD, Roland Suck, PhD, Hanns Meyer, Dipl Math,

Altered metabolic profile in patients with IgE to galactose-alpha-1,3-galactose following in vivo food challenge John W. Steinke, PhD, Shawna L. Pochan,

Casein-related anaphylaxis after use of an Everlast kickboxing glove

Different IgE recognition of mite allergen components in asthmatic and nonasthmatic children Yvonne Resch, MSc, Sven Michel, MSc, Michael Kabesch, MD,

Corinne A. Keet, MD, MS, Pamela A

Robert A. Wood, MD, Alkis Togias, MD, Jeremy Wildfire, MS, Cynthia M

Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis Thomas B. Casale, MD, William.

Development and cross-sectional validation of the Childhood Asthma Control Test Andrew H. Liu, MD, Robert Zeiger, MD, Christine Sorkness, PharmD, Todd.

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

House dust mite sublingual immunotherapy: Results of a US trial

Brian P. Vickery, MD, Jelena P. Berglund, PhD, Caitlin M

The natural history of IgE-mediated cow's milk allergy

Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1–derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis:

Jessica H. Savage, MD, MHS, Elizabeth C. Matsui, MD, MHS, Robert A

Long-lasting effects of sublingual immunotherapy according to its duration: A 15-year prospective study Maurizio Marogna, MD, Igino Spadolini, MD, Alessandro.

A bioinformatics approach to identify patients with symptomatic peanut allergy using peptide microarray immunoassay Jing Lin, PhD, Francesca M. Bruni,

Cindy Thamrin, PhD, Joel Zindel, Regula Nydegger, MD, Helen K

Long-term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy Stacie M. Jones, MD, A.

Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge Vernon M. Chinchilli, PhD, Laura Fisher, MD, Timothy.

The natural history of milk allergy in an observational cohort

Sublingual immunotherapy for peanut allergy: Clinical and immunologic evidence of desensitization Edwin H. Kim, MD, J. Andrew Bird, MD, Michael Kulis,

Paradoxical psoriasis following anti–TNF therapy in ankylosing spondylitis: A population- based cohort study Jung Min Bae, MD, PhD, Hyuck Sun Kwon, MD,

Priscilla A. Zetstra–van der Woude, MSc, J. Sebastiaan Vroegop, MD, H

Natural history of cow’s milk allergy

The Editors’ Choice Journal of Allergy and Clinical Immunology

Modeling asthma exacerbations through lung function in children

Presentation transcript:

Predicting development of sustained unresponsiveness to milk oral immunotherapy using epitope-specific antibody binding profiles Mayte Suárez-Fariñas, PhD, Maria Suprun, MPH, Helena L. Chang, MS, Gustavo Gimenez, BS, Galina Grishina, MS, Robert Getts, PhD, Kari Nadeau, MD, Robert A. Wood, MD, Hugh A. Sampson, MD Journal of Allergy and Clinical Immunology Volume 143, Issue 3, Pages 1038-1046 (March 2019) DOI: 10.1016/j.jaci.2018.10.028 Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Journal of Allergy and Clinical Immunology 2019 143, 1038-1046DOI: (10 Journal of Allergy and Clinical Immunology 2019 143, 1038-1046DOI: (10.1016/j.jaci.2018.10.028) Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Changes induced by MOIT in epitope-specific IgE or IgG4 binding by adjuvant treatment arm. A, Heat map representing (standardized) binding of 108 epitopes (48 IgE and 60 IgG4), with significant changes (fold change [FCH] > 1.5 and FDR ≤ 0.05) at month 32 from baseline. B, Box plot of the MOIT-induced log2 FCHs in epitope binding by adjuvant treatment. C, Bar plots of MOIT-induced changes and 95% CIs in log10 levels of SCPs. Asterisks represent a significant change at month 32 from baseline: *P < .05, **P < .01, and ***P < .001. DS, Desensitization; β-LG, β-lactoglobulin. Journal of Allergy and Clinical Immunology 2019 143, 1038-1046DOI: (10.1016/j.jaci.2018.10.028) Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Changes in ESAB by adjuvant treatment and MOIT outcome. A and B, Bar plots representing changes induced by MOIT in patients achieving only desensitization (DS) or SU by adjuvant treatment arm for each IgE and IgG4 epitope. The height of the bars represents the log2 fold change (FCH) in binding from baseline to month 32. Colors represent the direction of change (red, increase; blue, decrease) for the differential epitope-specific antibody binding (DESAB; FCH > 1.5 and FDR < 0.05). Colored asterisks indicate significance in changes between SU and DS outcomes for each adjuvant treatment (light blue, placebo; light pink, omalizumab); black asterisks represent DESAB, with significant differences between omalizumab and placebo for each outcome. C, Box plot of MOIT-induced changes in ESAB by MOIT outcome. NR, Nonresponder. Journal of Allergy and Clinical Immunology 2019 143, 1038-1046DOI: (10.1016/j.jaci.2018.10.028) Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 Differences in baseline epitope and SCP levels between groups achieving desensitization (DS) or SU 8 weeks after MOIT discontinuation. A, Box plots of the baseline overall (z score) epitope-specific IgE binding by MOIT outcome, with significantly different z scores between the SU and DS groups. NR, Nonresponders. B, Heat map representing baseline epitope-specific IgE binding for each patient for the set of epitopes with significant differences (fold change [FCH] > 1.5 and FDR < 0.05) between DS and SU outcomes at baseline. β-LG, β-Lactoglobulin. C, Bar plots of the least square mean (lsmean) with the 95% CI of log10 SCP levels at baseline by MOIT outcome. Journal of Allergy and Clinical Immunology 2019 143, 1038-1046DOI: (10.1016/j.jaci.2018.10.028) Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 4 Prediction of desensitization (DS) versus SU outcome at month 32 (8 weeks after MOIT discontinuation) by using baseline levels with machine learning algorithms. A, Performance metrics of models fitted with different features: epitope-specific IgE or IgG4 binding only, SCPs (total IgE; milk-specific IgE; casein-specific IgE, IgG, and IgG4; and β-lactoglobulin–specific IgE and IgG), or the combination of SCPs and IgE and IgG4 epitopes in 300 bootstrapping simulations. Means and 95% CIs are presented. IgE epitopes are sufficient to achieve maximal predictive performance. Accuracy and receiver operating characteristic (ROC) curve are presented here; other metrics can be found in Fig E8. B, ROC curve and coefficients for the best model with the 6 most robust IgE epitopes identified as important predictors in at least 75% of the bootstrapping simulations (BF = 75%). C, Predicted probabilities (x-axis) versus actual MOIT outcomes of all subjects (colored bars) as predicted by using an IgE-based epitope model with a BF of 75%. If the predicted probability is greater than 0.5, the subject is classified as SU and DS otherwise. Pink and red bars represent actual MOIT outcomes: DS (pink) and SU (red). D, Performance metrics of 4 models, including epitopes with BFs of 60% to 80%. Estimates with 95% CIs are presented for cross-validation (CV) statistics. Journal of Allergy and Clinical Immunology 2019 143, 1038-1046DOI: (10.1016/j.jaci.2018.10.028) Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions